Advice
following a full submission:
emtricitabine/tenofovir disoproxil (Truvada®) is accepted for use within NHS Scotland.
Indication under review: In combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.
In the pivotal studies conducted in men who have sex with men (iPrEx) and heterosexual couples, one of whom was HIV negative (Partners PrEP), there were statistically significant relative reductions in incidence of HIV for emtricitabine/tenofovir disoproxil compared with placebo.
Download detailed advice368KB (PDF)
Medicine details
- Medicine name:
- emtricitabine/tenofovir disoproxil (Truvada)
- SMC ID:
- 1225/17
- Indication:
- In combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 April 2017